Index RUT
P/E -
EPS (ttm) -5.42
Insider Own 2.33%
Shs Outstand 96.44M
Perf Week 16.23%
Market Cap 2.24B
Forward P/E -
EPS next Y -5.64
Insider Trans -2.33%
Shs Float 94.19M
Perf Month -6.85%
Income -481.19M
PEG -
EPS next Q -1.37
Inst Own 88.64%
Short Float 15.49%
Perf Quarter -7.88%
Sales 36.27M
P/S 61.87
EPS this Y -1.29%
Inst Trans -0.30%
Short Ratio 9.78
Perf Half Y -7.11%
Book/sh 11.29
P/B 2.06
EPS next Y -2.69%
ROA -34.11%
Short Interest 14.59M
Perf Year -37.11%
Cash/sh 9.46
P/C 2.46
EPS next 5Y 30.00%
ROE -42.10%
52W Range 19.37 - 47.48
Perf YTD -23.68%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -41.96%
52W High -50.99%
Beta 1.85
Dividend TTM -
Quick Ratio 8.67
Sales past 5Y 12.09%
Gross Margin 75.26%
52W Low 20.13%
ATR (14) 1.29
Dividend Ex-Date -
Current Ratio 8.67
EPS Y/Y TTM 12.31%
Oper. Margin -1420.51%
RSI (14) 49.11
Volatility 6.57% 4.87%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -30.40%
Profit Margin -1326.51%
Recom 1.54
Target Price 69.57
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -4.64%
Payout -
Rel Volume 0.82
Prev Close 22.50
Sales Surprise -115.04%
EPS Surprise -1.49%
Sales Q/Q -114.12%
Earnings May 09 BMO
Avg Volume 1.49M
Price 23.27
SMA20 2.14%
SMA50 -11.10%
SMA200 -23.16%
Trades
Volume 1,217,450
Change 3.42%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
Today 07:30AM
06:04AM
Apr-29-24 07:30AM
Apr-25-24 11:21AM
10:01AM
05:55AM
Loading…
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
01:43PM
Loading…
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Loading…
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
Index S&P 500
P/E 30.42
EPS (ttm) 7.30
Insider Own 1.14%
Shs Outstand 181.50M
Perf Week -5.06%
Market Cap 40.43B
Forward P/E 17.71
EPS next Y 12.54
Insider Trans -3.80%
Shs Float 179.95M
Perf Month -8.58%
Income 1.36B
PEG 2.65
EPS next Q 2.66
Inst Own 90.99%
Short Float 1.59%
Perf Quarter 5.13%
Sales 14.96B
P/S 2.70
EPS this Y 8.93%
Inst Trans 0.41%
Short Ratio 3.03
Perf Half Y 22.84%
Book/sh 33.67
P/B 6.60
EPS next Y 12.87%
ROA 5.22%
Short Interest 2.85M
Perf Year 19.69%
Cash/sh 8.22
P/C 27.03
EPS next 5Y 11.48%
ROE 22.87%
52W Range 167.42 - 261.73
Perf YTD -3.99%
Dividend Est. -
P/FCF 26.95
EPS past 5Y 42.42%
ROI 6.96%
52W High -15.13%
Beta 1.56
Dividend TTM -
Quick Ratio 0.86
Sales past 5Y 7.76%
Gross Margin 27.35%
52W Low 32.68%
ATR (14) 6.09
Dividend Ex-Date -
Current Ratio 0.86
EPS Y/Y TTM 27.39%
Oper. Margin 13.63%
RSI (14) 33.33
Volatility 2.76% 2.43%
Employees 87000
Debt/Eq 2.33
Sales Y/Y TTM 3.75%
Profit Margin 9.08%
Recom 1.62
Target Price 274.59
Option/Short Yes / Yes
LT Debt/Eq 2.19
EPS Q/Q 111.43%
Payout 0.00%
Rel Volume 1.80
Prev Close 232.94
Sales Surprise 0.99%
EPS Surprise 2.33%
Sales Q/Q 3.20%
Earnings May 02 BMO
Avg Volume 943.19K
Price 222.14
SMA20 -5.50%
SMA50 -9.24%
SMA200 0.74%
Trades
Volume 1,697,680
Change -4.64%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-26-24 Initiated
Leerink Partners
Outperform
$290
Feb-15-24 Downgrade
Guggenheim
Buy → Neutral
Feb-13-24 Initiated
BTIG Research
Buy
$285
Nov-02-23 Downgrade
Robert W. Baird
Outperform → Neutral
$248 → $202
Sep-06-23 Initiated
HSBC Securities
Buy
$260
Mar-17-23 Initiated
Truist
Buy
$265
Dec-06-22 Initiated
Cowen
Outperform
$251
Nov-17-22 Downgrade
Citigroup
Buy → Neutral
$275 → $245
Aug-25-22 Initiated
Credit Suisse
Outperform
$300
Jul-15-22 Initiated
SVB Leerink
Outperform
$256
May-24-22 Initiated
Guggenheim
Buy
$244
Apr-29-22 Upgrade
Piper Sandler
Neutral → Overweight
$231 → $255
Apr-25-22 Downgrade
Wells Fargo
Overweight → Equal Weight
$235
Aug-05-21 Resumed
Credit Suisse
Outperform
$272
Apr-16-21 Upgrade
Stephens
Equal-Weight → Overweight
$180 → $250
Mar-08-21 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$218
Mar-03-21 Initiated
Barclays
Overweight
$220
Jul-07-20 Initiated
Stephens
Equal-Weight
$150
Mar-02-20 Initiated
Deutsche Bank
Buy
$190
Jan-08-20 Initiated
Wells Fargo
Overweight
$180
Show Previous Ratings
Today 11:55AM
11:47AM
10:12AM
08:10AM
08:04AM
07:11AM
Loading…
07:11AM
(Associated Press Finance)
07:00AM
May-01-24 04:30PM
Apr-29-24 10:26AM
09:16AM
Apr-25-24 11:34AM
10:02AM
Apr-24-24 12:34PM
Apr-23-24 09:00AM
Apr-18-24 05:00PM
12:00PM
Loading…
Apr-17-24 12:00PM
Apr-15-24 04:15PM
Apr-08-24 04:01PM
07:41AM
Apr-04-24 09:40AM
09:08AM
Apr-02-24 11:39AM
Mar-20-24 07:44PM
Mar-15-24 01:38PM
11:30AM
Mar-13-24 12:07PM
Mar-06-24 04:15PM
Feb-27-24 08:00AM
Feb-26-24 08:00AM
Feb-23-24 09:00AM
04:15PM
Loading…
Feb-21-24 04:15PM
Feb-16-24 12:02AM
Feb-15-24 05:34PM
10:39AM
01:30AM
(Thomson Reuters StreetEvents)
Feb-14-24 06:29PM
(Morningstar Research) +13.10%
01:00PM
09:30AM
08:10AM
07:36AM
07:33AM
07:16AM
(Associated Press Finance)
07:00AM
Feb-09-24 09:26AM
09:15AM
Feb-06-24 09:00AM
Jan-24-24 04:15PM
Jan-18-24 12:49PM
Jan-17-24 06:00AM
Jan-10-24 06:29PM
06:16PM
Jan-03-24 10:31AM
Jan-02-24 08:15AM
Dec-29-23 09:31PM
09:18PM
Dec-28-23 06:30PM
Dec-07-23 11:53AM
Dec-01-23 11:31AM
Nov-29-23 08:30AM
Nov-21-23 04:15PM
Nov-20-23 12:34PM
Nov-17-23 09:23AM
Nov-15-23 09:11AM
Nov-14-23 09:07AM
Nov-06-23 08:00AM
Nov-04-23 01:18PM
Nov-02-23 03:52PM
11:25AM
09:30AM
01:15AM
Nov-01-23 11:43PM
(Thomson Reuters StreetEvents)
11:36AM
09:36AM
08:34AM
08:25AM
08:16AM
08:04AM
07:30AM
(Associated Press Finance)
07:00AM
Oct-30-23 04:21PM
10:00AM
Oct-26-23 12:10PM
10:45AM
Oct-25-23 10:02AM
Oct-23-23 08:00AM
Oct-20-23 07:39AM
04:23AM
Oct-19-23 06:54AM
Oct-17-23 09:07AM
Oct-11-23 07:30AM
Oct-09-23 04:15PM
07:19AM
Oct-05-23 08:13AM
08:00AM
Oct-03-23 08:00AM
Sep-29-23 03:57PM
03:15PM
Sep-25-23 08:01PM
Sep-14-23 12:44PM
Sep-12-23 08:30AM
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BOUSBIB ARI See Remarks Mar 01 '24 Option Exercise 65.16 42,847 2,791,911 828,430 Mar 04 05:28 PM BOUSBIB ARI See Remarks Mar 01 '24 Sale 250.53 31,678 7,936,193 796,752 Mar 04 05:28 PM STAUB W RICHARD See Remarks Feb 29 '24 Sale 247.80 14,100 3,494,034 15,945 Mar 04 05:27 PM Knightly Kevin C See Remarks Feb 28 '24 Option Exercise 87.40 13,206 1,154,211 13,858 Mar 01 05:07 PM Knightly Kevin C See Remarks Feb 28 '24 Sale 250.17 8,607 2,153,176 5,251 Mar 01 05:07 PM Knightly Kevin C See Remarks Feb 16 '24 Option Exercise 78.21 12,149 950,173 18,061 Feb 21 05:07 PM Knightly Kevin C See Remarks Feb 16 '24 Sale 241.10 13,468 3,247,165 652 Feb 21 05:07 PM Sherbet Eric See Remarks Feb 16 '24 Sale 241.50 1,000 241,500 20,836 Feb 21 05:08 PM Knightly Kevin C See Remarks Dec 01 '23 Option Exercise 62.26 18,491 1,151,185 20,464 Dec 05 05:01 PM Knightly Kevin C See Remarks Dec 01 '23 Sale 214.03 13,117 2,807,472 7,347 Dec 05 05:01 PM Panagos Constantinos See Remarks Sep 19 '23 Option Exercise 149.45 26,186 3,913,563 40,436 Sep 21 05:01 PM Panagos Constantinos See Remarks Sep 19 '23 Sale 208.67 27,317 5,700,340 14,250 Sep 21 05:01 PM Knightly Kevin C See Remarks Jun 05 '23 Sale 201.89 5,820 1,175,000 0 Jun 07 05:31 PM Knightly Kevin C See Remarks May 26 '23 Sale 198.66 1 199 0 May 31 09:29 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite